Welcome to our dedicated page for Opko Health news (Ticker: OPK), a resource for investors and traders seeking the latest updates and insights on Opko Health stock.
OPKO Health Inc. (NASDAQ: OPK) is a diversified healthcare company focused on establishing leading positions in large, rapidly growing markets. OPKO operates through two main segments: Diagnostics and Pharmaceuticals.
OPKO's Diagnostics segment includes BioReference Laboratories, the nation's third largest clinical laboratory. BioReference offers a comprehensive range of diagnostic services and features a core genetic testing business supported by a skilled 400-person sales and marketing team. Notable products include the 4Kscore® test for prostate cancer and the Claros® 1 in-office immunoassay platform.
The Pharmaceutical segment of OPKO showcases a diverse portfolio of products. Rayaldee, an FDA-approved treatment for secondary hyperparathyroidism in stage 3-4 chronic kidney disease patients with vitamin D insufficiency, was launched in November 2016. Other significant pharmaceutical developments include Varubitm for chemotherapy-induced nausea and vomiting, OPK88004 for type 2 diabetes and obesity, and OPK88003, a selective androgen receptor modulator for benign prostatic hyperplasia, both of which are in Phase 2 clinical trials.
OPKO has recently made headlines with strategic collaborations and technological advancements. BioReference Health, a subsidiary of OPKO, has entered a strategic alliance with SOPHiA GENETICS to incorporate MSK-ACCESS® liquid biopsy technology. This partnership aims to enhance BioReference's genomic analysis capabilities and offer state-of-the-art cancer testing across the U.S. Another collaboration with Prognos Health aims to merge genomic data with real-world data, facilitating precision medicine and improving patient outcomes.
Financially, OPKO continues to exhibit a strong performance with ongoing projects and strategic acquisitions. The acquisition of select assets from BioReference Health by Labcorp is set to expand OPKO's reach and capabilities, strengthening its market presence.
Headquartered in Miami, Florida, OPKO Health is committed to improving healthcare through innovation, scientific expertise, and strategic partnerships. For more detailed information about their products, services, and latest news, visit www.opko.com.
OPKO Health, Inc. (NASDAQ: OPK) will report its Q2 2021 operating and financial results on July 29, 2021, after U.S. market close. The company will provide a detailed business update during a conference call at 4:30 PM ET on the same day. Interested parties can pre-register for the call or access it via the provided webcast link. OPKO focuses on biopharmaceuticals and diagnostics, aiming to lead in rapidly growing markets through innovative technologies. Additional details and a replay will be available on OPKO's website.
OPKO Health, Inc. (NASDAQ: OPK) has entered into a worldwide agreement with CAMP4 Therapeutics for developing therapeutics based on the AntagoNAT technology. This agreement marks a significant step in advancing OPKO's lead compound for Dravet syndrome into clinical trials. OPKO will receive an upfront payment and is eligible for up to $93.5 million in milestone payments, plus royalties on product sales. The collaboration not only enhances OPKO’s focus on drug development but also validates its proprietary technology.
OPKO Health, Inc. (NASDAQ: OPK) will participate in the virtual Ladenburg Thalmann Healthcare Conference on July 13-14, 2021. Management will engage in a fireside chat on July 13 at 8:30 a.m. Eastern Time and will conduct one-on-one virtual meetings with investors throughout the day. The fireside chat will be archived in OPKO Health's Investors section on their website for future viewing. OPKO is focused on establishing a strong market position in biopharmaceuticals and diagnostics, leveraging its innovative technologies.
OPKO Health, Inc. (NASDAQ: OPK) has appointed Katherine Stueland as President and CEO of its subsidiary, GeneDx, Inc. Stueland, previously a Chief Commercial Officer at Invitae Corporation, brings two decades of leadership in the healthcare industry. Under her guidance, GeneDx aims to leverage genomic information to enhance patient care, emphasizing access to diagnostics for rare genetic disorders. The company has been a leading player in genomics for over 20 years, offering a wide array of genetic testing services.
BioReference Laboratories, a subsidiary of OPKO Health (NASDAQ: OPK), has launched a COVID-19 testing program aimed at U.S. crew and guests cruising with Royal Caribbean Group. This program mandates rapid PCR testing for unvaccinated guests prior to embarkation and at the end of their voyage, with additional testing during the cruise as needed. The initiative is designed to enhance safety for travelers, providing results within 40 minutes of arrival at the port. BioReference, a leading lab in the U.S., serves approximately 19 million patients annually and offers extensive testing solutions.
OPKO Health, Inc. (NASDAQ: OPK) has announced a partnership between its subsidiary EirGen Pharma and Nicoya Macau Limited for the commercialization of RAYALDEE in Greater China. The agreement includes an upfront payment of $5 million and additional payments contingent on development milestones, totaling up to $115 million. Nicoya will handle regulatory approvals and commercialization. With an estimated 19 million patients with stage 3 or 4 chronic kidney disease in the region, this collaboration aims to tap into a significant market opportunity.
OPKO Health, Inc. (NASDAQ: OPK) announced that its subsidiary, EirGen Pharma, has agreed to sell its Waterford, Ireland facility to Horizon Therapeutics for $65 million. This sale will streamline EirGen’s operations, focusing on oral solid dose products. CEO Phillip Frost emphasized the transaction strengthens OPKO's balance sheet while cutting expenses and enhancing efficiency. The deal is expected to close in about a month, pending governmental approvals.
OPKO Health (NASDAQ: OPK) will participate in the Jefferies Virtual Healthcare Conference from June 1-4, 2021. Management will engage in a fireside chat on June 2 at 11:30 a.m. Eastern time. The chat will be available via live webcast and archived on OPKO Health’s investor website. Additionally, one-on-one virtual meetings with investors will occur throughout the day. OPKO Health focuses on biopharmaceuticals and diagnostics, aiming to lead in growing markets through innovative technologies.
OPKO Health (NASDAQ: OPK) has transferred the rights to its product RAYALDEE® in Japan from Japan Tobacco (JT) to Vifor Fresenius Medical Care Renal Pharma (VFMCRP). The agreement follows JT's decision to terminate its exclusive rights based on a review of its pipeline. EirGen Pharma will now work with VFMCRP under an existing agreement for the product's commercialization in Japan and other markets. RAYALDEE® treats secondary hyperparathyroidism in chronic kidney disease patients and is approved in the U.S. and 11 European countries.
OPKO Health, Inc. (NASDAQ: OPK) has entered into exchange agreements with certain noteholders to convert $55.42 million of its 4.50% Convertible Senior Notes due 2025 into shares of common stock. The exchange will be based on a volume-weighted average price with a floor price of $3.50 per share, starting today. Additionally, OPKO will pay accrued interest to the noteholders in cash. This move is expected to reduce the outstanding borrowed shares related to a previous share lending agreement with Jefferies Capital Services.
FAQ
What is the current stock price of Opko Health (OPK)?
What is the market cap of Opko Health (OPK)?
What does OPKO Health Inc. specialize in?
What are the main products offered by OPKO Health?
What recent collaborations has OPKO Health announced?
Where is OPKO Health headquartered?
What is the significance of the 4Kscore® test?
How does BioReference Laboratories fit into OPKO Health's operations?
What is Rayaldee used for?
What impact will the Labcorp acquisition have on OPKO Health?
What are the future goals of OPKO Health?
How can investors learn more about OPKO Health's performance?
